Form 4 for DNLI Denali Therapeutics Inc.
Accepted 2025-01-08 00:00:00 ET · period of report 2025-01-06 · accession 0001714899-25-000051 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2025-01-08 | 2025-01-06+ | DNLI | Ho Carole | Chief Medical Off | S - Sale | $20.33 | -15.2K | 175.7K | -8% | -$308.3K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-01-06 | S | D | 12,255 | $20.22 | 178,580 | D | — | — | (F2) The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $19.93 to $20.23 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. (F3) Includes 134,030 Unvested RSUs. |
| 2 | Common | Common Stock | 2025-01-07 | S | D | 2,907 | $20.81 | 175,673 | D | — | — | (F3) Includes 134,030 Unvested RSUs. |